A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to A
Research payments
$687,926
Through program year 2025, $687,926 in research payments was reported against A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to A, across 122 payments, paid by GlaxoSmithKline, LLC..
- Paid by
- GlaxoSmithKline, LLC.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
2 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $643,523 | 101 |
| 2024 | Research | $44,404 | 21 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
7 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Ronald Nahass New Brunswick, NJ Named on 64 payments
- Federico Hinestrosa Orlando, FL Named on 21 payments
- Mark Sulkowski Lutherville, MD Named on 18 payments
- Hector Bolivar Miami, FL Named on 8 payments
- Maurizio Bonacini Eureka, CA Named on 5 payments
- Amanda Noska Minneapolis, MN Named on 4 payments
- Franco Felizarta Bakersfield, CA Named on 2 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.